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Background: Previously, MDR1  T-129C polymorphism, encoding multidrug resistant transporter 
MDR1/P-glycoprotein, was reported to be predictive of poorly-differentiated colorectal adenocarcinomas. Here, 
VEGF T-1498C, C-634G and C-7T polymorphisms, encoding vascular endothelial growth factor (VEGF), were 
investigated in terms of their association with differentiation grade.   
Methods: VEGF genotypes were determined by TaqManR MGB probe based polymerase chain reaction and 
evaluated were confirmed by direct sequencing in 36 Japanese patients.   
Results: VEGF T-1498C, but not C-634G or C-7T, was predictive of poorly-differentiated ones, and thereby a 
poor prognosis (p = 0.064 for genotype, p = 0.037 for allele), and this effect can be explained by that on VEGF 
expression. Treatment of a colorectal adenocarcinoma cell line, HCT-15, with sodium butyrate, a typical differ-
entiating agent, resulted in an increase of alkaline phosphatase activity and MDR1 mRNA expression, but in a 
decrease of VEGF mRNA expression. The transfection of VEGF small interfering RNA (siRNA) induced the ex-
pression of MDR1 mRNA to 288-332% of the control level, whereas MDR1 siRNA had no effect on VEGF mRNA 
expression.  
Conclusions: VEGF T-1498C polymorphism is also a candidate marker predictive of poorly-differentiated colo-
rectal adenocarcinomas, but further investigations with a large number of patients should be addressed to draw 
a conclusion. 
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1.  Introduction 
Numerous clinicopathological factors have been 
reported to have prognostic significance for colorectal 
cancer, including tumor invasion, nodal metastasis, 
differentiation, and lymphocytic infiltration [1]. The 
importance of differentiation was already suggested in 
the 1920s, and the tumors have been graded into well-, 
moderately- and poorly-differentiated types. Most of 
colorectal cancers are assessed as well- or moder-
ately-differentiated adenocarcinoma in the Japanese 
[2, 3]; that is, Takeuchi et al.[3] reported poorly-, mod-
erately- and well-differentiation types were found at 
3.3%, 77.2% and 19.5% in adenocarcinomas, respec-
tively. The 5-year survival rate depended on the dif-
ferentiation grade, and for well-differentiated types 
was reported to be 71-72%, but in contrast, it was only 
32-46% for poorly-differentiated adenocarcinoma in 
Japanese, although we have rarely encountered this 
type [2, 3]. Thus, it is important to evaluate differen-
tiation grade accurately to decide a management 
strategy; however, its usefulness is sometimes thought 
to be limited due to difficulties in assessment and 
thereby reproducibility, encouraging us to search for Int. J. Med. Sci. 2008, 5 
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alternative molecular markers [4], or to establish a 
method of subclassification [3]. 
We have been conducting a series of clinical 
and/or non-clinical investigations to find an invasive, 
if possible, noninvasive marker predictive of the dif-
ferentiation and thereby prognosis of colorectal ade-
nocarcinoma [5-7]. The mRNA expression level of 
vascular endothelial growth factor (VEGF), an endo-
thelial cell-specific mitogen and survival factor, was 
analyzed using tissue samples obtained from 18 Japa-
nese patients with colorectal adenocarcinoma, and its 
association with 12 genotypes of VEGF; C-2578A, 
G-1877A, T-1498C, T-1455C, G-1190A, and G-1154A in 
the promoter region, C-634G and C-7T in the 5’ un-
translated region (5’UTR), and C702T, C936T, C1451T, 
and G1612A in the 3’UTR, were examined. It was con-
cluded that 1) VEGF mRNA expression was 
up-regulated in colorectal adenocarcinomas compared 
to adjacent noncancerous colorectal tissues, 2) 
C-2578A, G-1154A, and G1612A might be associated 
with a decreased risk of colorectal adenocarcinoma, 
and 3) T-1498C (in linkage with G-1190A), C-7T, and 
possibly C-634G, were associated with higher levels of 
VEGF mRNA in colorectal adenocarcinomas, but not 
in adjacent noncancerous colorectal tissues [5]. In con-
trast, it was found that 1) mRNA expression of mul-
tidrug resistant transporter MDR1/P-glycoprotein, the 
gene product of MDR1, was down-regulated in colo-
rectal adenocarcinomas compared to adjacent non-
cancerous colorectal tissues obtained from 21 patients 
[6], 2) 4 major genetic polymorphisms of MDR1 
T-129C in the promoter region, C1236T (silent) in exon 
12, G2677A,T in exon 21 resulting in Ala893Thr,Ser, 
and C3435T (silent) in exon 26 were not associated 
with disease risk after an analysis of peripheral blood 
of 48 patients [7], and 3) T-129C was associated with 
lower levels of MDR1 mRNA both in colorectal ade-
nocarcinomas and in adjacent noncancerous colorectal 
tissues [6]. Taken together, it was suggested that 
VEGF expression would be linked with MDR1 expres-
sion, and their genetic polymorphisms might be 
promising markers of the prognosis of colorectal ade-
nocarcinoma. In this study, VEGF T-1498C, C-634G, 
and C-7T were evaluated in 36 Japanese patients with 
colorectal adenocarcinoma, and their associations with 
differentiation grade were analyzed. A colorectal can-
cer cell line, HCT-15, was treated with sodium bu-
tyrate (NaB), a typical differentiating agent, and al-
terations of alkaline phosphatase (ALP) activity, an 
index of differentiation, and VEGF mRNA expression 
level were assessed. In addition, the effects of VEGF or 
MDR1 small interfering RNA (siRNA) on their mRNA 
expression were assessed.   
2.  Materials and Methods 
Patients  
Thirty-six Japanese patients with colorectal ade-
nocarcinoma diagnosed at Kobe University Hospital 
(24 men and 12 women) were enrolled in this study. 
The average age was age 64.6±9.3 years ( ±SD; range, 
34-78). A standard treatment protocol was scheduled, 
and the data on differentiation grade were obtained 
from medical records. Informed consent was obtained 
from all subjects prior to their participation in the 
study, which was approved by the Institutional Re-
view Broad of Kobe University Hospital, Kobe Uni-
versity, Japan.  
VEGF Genotyping  
Genomic DNA was extracted from peripheral 
blood using a DNeasy Tissue KitR (QIAGEN, Hilden, 
Germany) according to the manufacturer’s directions. 
In this study, VEGF T-1498C, C-634G and C-7T were 
determined by TaqManR MGB probe based poly-
merase chain reaction. The sequences of forward and 
reverse primers and 2 probes for T-1498C and C-7T, 
synthesized by Applied Biosystems, Foster City, CA, 
USA, are listed in Table 1. VEGF C-634G was assessed 
using a kit (TaqManR SNP Genotyping Assay, part. 
No. C_8311614_10, Applied Biosystems). The geno-
types evaluated were confirmed by direct sequencing 
using an automatic ABI PRISM 310 Genetic Analyzer 
(Applied Biosystems) as described in our previous 
report [5]. The primers used for direct sequencing 
were synthesized by Hokkaido System Science, Co., 
Ltd. (Sapporo, Japan).  
Table 1. Sequences of primers and probes used for VEGF 
T-1498C and C-7T genotyping 
T-1498C   
Forward primer  GTGTGGGTGAGTGAGTGTGT 
Reverse primer  GTGACCCCTGGCCTTCTC 
T-1498-allele probe  VIC-CTCCAACaCCCTCAAC 
C-1498-allele probe  FAM-CCAACgCCCTCAAC 
C-7T    
Forward primer  CCGAGCCGGAGAGGGA 
Reverse primer  GCACCCAAGACAGCAGAAAGT 
C-7-allele probe  VIC-CATGGTTTCgGAGGCC 
T-7-allele probe  FAM-ATGGTTTCaGAGGCC 
Effect of NaB on ALP activity and VEGF mRNA 
expression in HCT-15 cells  
A colorectal cancer cell line, HCT-15 (passage 43), 
were purchased from Dainippon Sumitomo Pharma 
Co., Ltd. (Osaka, Japan). HCT-15 cells were main-
tained in RPMI1640 culture medium (Invitrogen 
Corp., Carlsbad, CA, USA) supplemented with 
heat-inactivated 10% fetal bovine serum (FBS; CEL-
Lect® GOLD, MP Biomedicals, Irvine, CA, USA). The 
cells seeded at a density of 3.0×106 cells in 40 ml of 
culture medium in 175 cm2 culture flasks (NunclonTM, Int. J. Med. Sci. 2008, 5 
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Nalge Nunc International, NY, USA) were grown in 
an atmosphere of 95% air and 5% CO2 at 37°C, and 
subcultured every 3-4 days using a mixture of 0.02% 
EDTA and 0.05% trypsin (Invitrogen Corp.). 
HCT-15 cells seeded at a density of 4x105 cells in 
2 ml of culture medium in a 6-well plate (NunclonTM, 
Nalge Nunc International) were grown in an atmos-
phere of 95% air and 5% CO2 at 37°C. After 24 hrs, the 
culture medium was replaced, and an aqueous solu-
tion of NaB, a typical differentiating agent, was added 
to give a final concentration of 1 or 5 mM for NaB. The 
volumetric concentration of purified water was less 
than 0.1%. After another 24, 48, and 72 hr, the cells 
were washed twice with ice-cold phosphate buffered 
saline, and cell pellets were prepared. The expression 
levels of VEGF mRNA were evaluated as described in 
our previous report [5]. The ALP activity was meas-
ured using a commercially available kit 
(LABOASSAYTM A L P ,  W a k o  P u r e  C h e m i c a l  I n d u s -
tries, Ltd., Osaka, Japan) in cell lysates prepared with 
an ultrasonic cell disrupter: the activity was assessed 
as the rate of conversion from p-nitrophenylphosphate 
to p-nitrophenol.  
Effect of transfixing VEGF or MDR1 siRNA on 
mRNA expression in HCT-15 cells 
The transfection of siRNA was performed as re-
ported [8, 9]. siRNA duplexes for VEGF and MDR1 
mRNA were synthesized by FASMAC, Co. (Kana-
gawa, Japan): VEGF (GenBank accession no. 
NM_001025366): sense (5’-CCA ACA UCA CCA UGC 
AGA UdTdT-3’), antisense (5’-AUC UGC AUG GUG 
AUG UUG GdTdT-3’); MDR1 (NM_000927): sense (5’- 
GGA GGA UUA UGA AGC UAA AdTdT -3’), an-
tisense (5’- UUU AGC UUC AUA AUC CUC CdTdT 
-3’) [10]. Scramble siRNA for VEGF and MDR1 was 
also designed based on the original target sequence: 
5’- UAA CAC AGC ACA CCU ACG UdTdT -3’ and 
5’-AAG AAG GCA UGG UUG UAA AdTdT-3’, re-
spectively. A mixture of 8 µl of OligofectamineTM Re-
agent (Invitrogen Corp.) and 22 µl of Opti-MEMR I 
Reduced-Serum Medium (Invitrogen Corp.) was in-
cubated at room temperature for 10 min. After that, 
360 µL of Opti-MEMR I Reduced-Serum Medium and 
10 µl of 20 µM siRNA aqueous solution were added, 
and the mixture was incubated at room temperature 
for 20 min, giving 400 µl of siRNA-Oligofectamine 
complexes. HCT-15 cells were seeded at a density of 
1.5×105 cells/well/2 ml in a 6-well plate. After 24 hr, 
the cells were washed twice with phosphate buffered 
saline, and supplied with 1600 µl of Opti-MEMR I Re-
duced-Serum Medium and 400 µl of 
siRNA-Oligofectamine complexes. This was followed 
by incubation for 4 hr. The reagents were replaced 
with RPMI1640 culture medium, and after another 24, 
48, and 72 hr, the cells were collected and subjected to 
assays of the mRNA expression of VEGF or MDR1. 
The data on cells treated without siRNA were used as 
a control.  
Statistical analysis  
Values are given as the mean ± standard devia-
tion (SD). The association of VEGF allelic or genotype 
frequencies with differentiation grade was assessed by 
the Fisher’s exact test. For the data on the effect of 
NaB, multiple comparisons were performed with an 
analysis of variance (ANOVA) followed by the Scheffé 
test, provided the variance was similar. If this was not 
the case, the Scheffé-type test was performed after the 
Kruskal-Wallis test. For the data on the effect of 
siRNA, the unpaired t test or the Mann-Whitney’s U 
test was performed. P values of less than 0.05 were 
considered significant. 
3.  Results and Discussion 
Table 2 lists the data on the association of VEGF 
T-1498C, C-634G and C-7T with differentiation grade. 
VEGF T-1498C, but not C-634G or C-7T, was sug-
gested to be predictive of poorly-differentiated colo-
rectal adenocarcinomas, and thereby a poor prognosis 
(p = 0.064 for genotype, p = 0.037 for allele). However, 
statistical analysis without the data of 
poorly-differentiated ones resulted in no difference (p 
= 0.153 for genotype, p = 0.128 for allele). Only a small 
number of patients enrolled in this study, and further 
investigations should be addressed to draw a conclu-
sion. 
Table 2. Association of VEGF T-1498C, C-634G, and C-7T 
with differentiation grade of colorectal adenocarcinomas in 
Japanese 
 N  well  moderately  poorly  p 
T-1498C          
TT 16  8  8  0  0.064 
TC 14  7  7  0   
CC 6 0  5  1   
T 46  23  23  0 0.037 
C 26  7  17  2   
C-634G          
CC 6 4  2  0  0.239 
CG 17 8  9  0   
GG 13 3  9  1   
C 29  16  13  0 0.124 
G 43  14  27  2   
C-7T          
CC 24  11  12  1  0.691 
CT 10  4  6  0   
TT 2  0  2  0   
C 58  26  30  2 0.590 
T 14  4  10  0   
 
VEGF, first termed vascular permeability factor 
(VPF), was discovered in the 1980s [11-16]. VEGF is 
now recognized to be a member of the VEGF gene Int. J. Med. Sci. 2008, 5 
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family, and in the new system of nomenclature, is de-
fined as VEGF-A [17-19]. VEGF is expected to be in-
volved in the pathogenesis of cancer metastasis, reti-
nopathy, age-related macular degeneration, rheuma-
toid arthritis, and psoriasis, and clinical observations 
have confirmed that VEGF expression in solid tumors 
is predictive of resistance to radiotherapy, chemo-
therapy, and endocrine therapy [17-19]. In patients 
with colorectal cancer, VEGF expression has been 
found to be associated with disease progression, mi-
crovessel density, venous invasion, lymph node 
and/or liver metastasis, and prognosis [20-24], al-
though reports have not always provided similar con-
clusions [25, 26]. In our previous report, VEGF 
T-1498C was found to be linked with higher levels of 
VEGF mRNA in colorectal adenocarcinomas [5]. The 
association of VEGF T-1498C with 
poorly-differentiated type as shown in Table 2 can be 
explained by its effect on VEGF expression, although 
differentiation grade-dependent VEGF expression was 
not demonstrated in our samples.   
The VEGF gene is located on chromosome 6p21.3 
and comprises a 14-kb coding region with 8 exons and 
7 introns, and alternative exon splicing results in the 
production of 4 major and several minor isoforms 
[17-19]. The genetically controlled variation in the 
production of VEGF was examined in peripheral 
blood mononuclear cells (PBMCs) or plasma [27-30]. 
C-2578A [28], G-1154A [28], and C936T [29, 30] were 
found to result in lower levels of VEGF production, 
and have recently been suggested to be associated 
with a reduce risk of breast cancer [30], prostate cancer 
[31], and cutaneous malignant melanomas [32]. Com-
pared with C-2578A, G-1154A and C936T, little infor-
mation is available for T-1498C. In Japanese, the 
TT/TC/CC ratio was reported to be 
44.1%/48.3%/7.6% for type 2 diabetic patients with-
out retinopathy [33], and to our knowledge, no infor-
mation was presented for healthy subjects, and 
T-1498C was expected to be less frequently found in 
Japanese than other races [27]. The TT/TC/CC ratio 
was 44.4%/38.9%/16.7% in Japanese patients with 
colorectal adenocarcinomas (Table 2), and T-1498C 
would not be a marker of susceptibility. 
Previously, MDR1 T-129C, but not G2677A,T or 
C3435T, was found to result in lower levels of MDR1 
mRNA both in colorectal adenocarcinomas and in ad-
jacent noncancerous colorectal tissues [6]. Relatively 
weak expression was suggested in moder-
ately-differentiated compared to well-differentiated 
colorectal adenocarcinomas [6]. No significant asso-
ciation was observed for the dependency of grade of 
differentiation on MDR1 expression, presumably be-
cause poorly-differentiated colorectal adenocarcino-
mas are infrequent in Japanese [6], but Potocnik et al. 
[34] indicated lower levels of MDR1 expression in 
poorly-differentiated than well-differentiated colorec-
tal cancers obtained from Slovenia patients, with in-
termediate levels of expression for moder-
ately-differentiated cancers. Collectively, it was con-
cluded that MDR1 T-129C might be predictive of 
poorly-differentiated colorectal adenocarcinomas, and 
thereby a poor prognosis [6]. MDR1 is a glycosylated 
membrane protein of 170 kDa, belonging to the 
ATP-binding cassette superfamily of membrane 
transporters [35-40]. MDR1 was originally isolated 
from resistant tumor cells as part of the mechanism of 
multidrug resistance. Human MDR1 has been found 
to be expressed throughout the body to confer intrin-
sic resistance to the tissues by exporting unnecessary 
or toxic exogenous substances or metabolites. Recent 
investigations have challenged the notion that MDR1 
has evolved merely to facilitate the efflux of xenobiot-
ics and have raised the possibility that MDR1 plays a 
fundamental role in regulating apoptosis. Given the 
down-regulation of MDR1 expression during the dif-
ferentiation of pluripotent stem cells along the mye-
loid lineage in 1991 [41], its potential implications in 
cell systems resulting in cell death or differentiation 
have been discussed for the last decade. Recently, we 
and Goto et al. have found that MDR1 mRNA expres-
sion is down-regulated in a human colon carcinoma 
cell line, Caco-2, prior to the up-regulation of the ex-
pression of villin mRNA, a marker of differentiation 
[42, 43]. A lower level of MDR1 mRNA in adenocar-
cinomas than adjacent noncancerous tissues suggests 
its down-regulation as a consequence of the malignant 
transformation of colorectal tissues, possibly with the 
suppression of differentiation [6]. Lower levels of 
MDR1 in cancerous tissues than the adjacent normal 
tissues were also reported in French patients with re-
nal cell carcinoma [44] and Japanese patients with co-
lorectal carcinoma [45], but the opposite result was 
obtained in French patients with advanced breast car-
cinoma [46]. Poorly-differentiated types are found in 
13.8-17.5% of Caucasians [47, 48], more frequent than 
in Japanese, suggesting a difference in the nature of 
the cancer between Caucasians and Japanese. Further 
clinical investigations might be needed to conclude 
the usefulness of MDR1 T-129C with regards to pre-
dictions of prognosis. 
Compared with adjacent noncancerous colorectal 
tissues, VEGF mRNA expression was up-regulated, 
but MDR1 mRNA expression was down-regulated in 
colorectal adenocarcinomas, suggesting their linkage 
[5, 6]. Fig. 1 shows the effect of NaB on ALP activity 
and VEGF mRNA expression in HCT-15 cells. ALP 
activity increased in a NaB-concentration and treat-Int. J. Med. Sci. 2008, 5 
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ment time-dependent manner, and VEGF mRNA ex-
pression was suppressed as ALP activity increased. In 
our previous report, treatment with NaB resulted in 
an up-regulation of MDR1 mRNA expression [6]. Fig. 
2 shows the effects of transfecting VEGF siRNA on the 
mRNA expression of VEGF and MDR1 in HCT-15 
cells. VEGF mRNA expression was suppressed; indi-
cating a successful transfection of VEGF siRNA, and 
under these conditions, MDR1 mRNA expression was 
increased to 288-332% of the control level. Fig. 3 shows 
the effects of transfecting MDR1 siRNA on the mRNA 
expression of VEGF and MDR1. MDR1 mRNA ex-
pression was suppressed, but VEGF mRNA expres-
sion was not altered. It should be that scramble siRNA 
for VEGF and MDR1 had no effect on the expression 
of either mRNA (data not shown). Taken together, it 
could be said that VEGF itself or the factors resulting 
in production of VEGF had a suppressive effect on 
MDR1 expression, suggesting that cancer patients 
with a higher VEGF expression will show a relatively 
high sensitivity for MDR1 substrates, including 
vinca-alkaloids, anthracyclines and taxanes. Consider-
ing that a number of factors affect MDR1 expression 
[35-40],  VEGF expression and/or genetic polymor-
phisms of VEGF were thought to be superior. 
In summary, VEGF T-1498C, but not C-634G or 
C-7T, was predictive of poorly-differentiated colorec-
tal adenocarcinomas, and thereby a poor prognosis. 
This effect can be explained by that on VEGF expres-
sion. In vitro experiments using HCT-15 cells have 
suggested that VEGF expression was linked with 
MDR1 expression. MDR1 T-129C was also reported to 
be predictive of poorly-differentiated colorectal ade-
nocarcinomas, and VEGF T-1498C polymorphism is 
also a candidate marker, but further investigations 
with a large number of patients should be addressed 
to draw a conclusion. 
 
Figure 1. Effect of NaB on ALP activity and VEGF mRNA 
expression in HCT-15 cells. HCT-15 cells were treated with 1 or 
5 mM NaB for 24, 48, and 72 hr, and ALP activity and VEGF 
mRNA levels were assessed. The results were expressed as the 
mean ± SD of 4 independent experiments. (A) ALP activity, (B) 
VEGF mRNA. Open column: control (0 mM NaB), closed 
column: 1 mM NaB, hatched column: 5 mM NaB. *: p < 0.05, 




Figure 2. Effect of VEGF siRNA on mRNA expression of 
VEGF and MDR1 in HCT-15 cells. HCT-15 cells were treated 
with VEGF siRNA for 24, 48, and 72 hrs, and mRNA expres-
sion levels of VEGF and MDR1 were assessed. The results were 
expressed as the mean ± SD of 3-4 independent experiments. 
(A) VEGF mRNA, (B) MDR1 mRNA. Open column: without 
VEGF siRNA, closed column: with VEGF siRNA. The scram-
ble siRNA for VEGF had no effect on the mRNA expression of 





Figure 3. Effect of MDR1 siRNA on mRNA expression of 
VEGF and MDR1 in HCT-15 cells. HCT-15 cells were treated 
with MDR1 siRNA for 24, 48, and 72 hr, and mRNA expression 
levels of VEGF and MDR1 were assessed. The results were 
expressed as the mean ± SD of 3-4 independent experiments. 
(A) VEGF mRNA, (B) MDR1 mRNA. Open column: without 
MDR1 siRNA, closed column: with MDR1 siRNA. The 
scramble siRNA for MDR1 had no effect on the mRNA ex-
pression of VEGF or MDR1. *: p < 0.05, when compared with 
no MDR1 siRNA. 
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